المؤلفون: Sergio Amadori, Franca Falzetti, Theo de Witte, Petra Muus, Giorgina Specchia, Roel Willemze, Paola Fazi, Zwi N. Berneman, Adriano Venditti, Marco Vignetti, Michael Lübbert, Jean-Pierre Marie, Jose E. Guimaraes, Roberto Stasi, Anthony D. Ho, Constantijn J. M. Halkes, Matthias Karrasch, Dominik Selleslag, Domenico Magro, Roberto Latagliata, Xavier Thomas, Paolo de Fabritiis, Stefan Suciu, Helmut R. Salih

المصدر: Journal of Clinical Oncology, 31(35), 4424
Journal of clinical oncology
Journal of Clinical Oncology, 31, 4424-30
Journal of Clinical Oncology, 31, 35, pp. 4424-30

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_treatment, chemotherapy, AML, Antineoplastic Combined Chemotherapy Protocols, Medicine, Etoposide, Remission Induction, Hazard ratio, Cytarabine, Translational research Immune Regulation [ONCOL 3], Induction Chemotherapy, Middle Aged, Gemtuzumab, Treatment Outcome, Liver, Oncology, Leukemia, Myeloid, GO, Go/no go, Acute Disease, Female, medicine.drug, medicine.medical_specialty, Gemtuzumab ozogamicin, Antibodies, Monoclonal, Humanized, Infections, Drug Administration Schedule, Mylotarg, karyotype, CD33 esxpression, Translational research [ONCOL 3], Internal medicine, Humans, Aged, Febrile Neutropenia, Chemotherapy, Mitoxantrone, business.industry, Induction chemotherapy, Survival Analysis, Surgery, Aminoglycosides, Human medicine, business, Settore MED/15 - Malattie del Sangue, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f6f2f3ec93f64b510497efe24e3162
http://hdl.handle.net/1887/99842